{"id":16259,"date":"2012-04-01T13:17:03","date_gmt":"2012-04-01T13:17:03","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=16259"},"modified":"2012-07-19T13:30:09","modified_gmt":"2012-07-19T13:30:09","slug":"fda-warning-of-drug-interactions-between-boceprevir-and-some-hiv-protease-inhibitors","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/16259","title":{"rendered":"FDA warning of drug interactions between boceprevir and some HIV protease inhibitors"},"content":{"rendered":"<p><strong>The US FDA have notified health care professional and patients that drug interactions between boceprevir and certain ritonavir- boosted HIV protease inhibitors (atazanavir, lopinavir and darunavir) can significantly reduce the effectiveness of these drugs when used together. [1]<\/strong><\/p>\n<p>Merck, the manufacturer\u2019s of boceprevir also issued a drug warning giving the pharmacokinetic data and the recommendation that \u201ccoadministering boceprevir and ritonavir-boosted PIs is not recommended\u201d. [2]<\/p>\n<p>Source: FDA list serve<\/p>\n<p>References:<\/p>\n<ol>\n<li>FDA warning. Victrelis (boceprevir) and ritonavir-boosted Human Immunodeficiency Virus (HIV) protease inhibitor drugs: drug safety communication &#8211; drug interactions, (9 February 2012).<br \/>\n<a href=\"http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm291144.htm\">http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm291144.htm<\/a><\/li>\n<li>Merck. Dear Healthcare Professional letter. Results of pharmacokinetic study in healthy volunteers given VICTRELIS (boceprevir) and ritonavir-boosted HIV protease inhibitors may indicate clinically significant drug interactions for patients coinfected with chronic hepatitis C and HIV. (6 February 2012).<br \/>\n<a href=\"http:\/\/www.merck.com\/newsroom\/pdf\/FINAL_DHCP_2_6_2012.pdf\">http:\/\/www.merck.com\/newsroom\/pdf\/FINAL_DHCP_2_6_2012.pdf<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>The US FDA have notified health care professional and patients that drug interactions between boceprevir and certain ritonavir- boosted HIV protease inhibitors (atazanavir, lopinavir and darunavir) can significantly reduce the effectiveness of these drugs when used together. [1] Merck, the &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-16259","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=16259"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/16259\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=16259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=16259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=16259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}